TECHWIRE 30
(CIX: WRAL30)  1,009.37  up arrow+12.92  (1.3 %)  Updated: 03:17 PM EDT, Apr 24 2014
(NQ: Apple)  569.76  up arrow+45.01  (8.58 %)  Updated: 03:18 PM EDT, Apr 24 2014
(NY: QUINTILES)  50.00  up arrow+0.53  (1.07 %)  Updated: 03:16 PM EDT, Apr 24 2014
(OP: BASF SE)  112.89  up arrow+0.3  (0.27 %)  Updated: 03:13 PM EDT, Apr 24 2014
(NQ: BioCryst)  8.46  down arrow-0.09  (-1.05 %)  Updated: 03:16 PM EDT, Apr 24 2014
(NQ: BioDelivery)  8.69  up arrow+0.03  (0.35 %)  Updated: 03:17 PM EDT, Apr 24 2014
(NQ: CEMP)  9.93  up arrow+0.01  (0.1 %)  Updated: 03:17 PM EDT, Apr 24 2014
(NQ: Cisco Systems)  23.33  down arrow-0.17  (-0.72 %)  Updated: 03:18 PM EDT, Apr 24 2014
(NQ: Cornerstone)  9.49    (0 %)  Updated: 08:10 PM EST, Feb 03 2014
(NQ: Cree)  50.08  down arrow-0.96  (-1.88 %)  Updated: 03:17 PM EDT, Apr 24 2014
(NQ: DARA)  1.90  up arrow+0.02  (1.01 %)  Updated: 03:17 PM EDT, Apr 24 2014
(NY: EMC CORPORATION)  25.51  down arrow-0.4  (-1.54 %)  Updated: 03:18 PM EDT, Apr 24 2014
(NQ: Extreme Networks)  5.67  down arrow-0.03  (-0.53 %)  Updated: 03:17 PM EDT, Apr 24 2014
(NQ: Facebook)  61.57  up arrow+0.21  (0.34 %)  Updated: 03:18 PM EDT, Apr 24 2014
(NY: GLAXOSMITHKLINE)  55.49  up arrow+0.35  (0.63 %)  Updated: 03:17 PM EDT, Apr 24 2014
(NQ: GOOG)  524.70  down arrow-2.24  (-0.43 %)  Updated: 03:17 PM EDT, Apr 24 2014
(NY: IBM)  190.66  down arrow-1.07  (-0.56 %)  Updated: 03:18 PM EDT, Apr 24 2014
(NY: LH)  100.22  up arrow+0.37  (0.37 %)  Updated: 03:17 PM EDT, Apr 24 2014
(OP: Lenovo Group)  22.56  down arrow-0.2  (-0.88 %)  Updated: 03:12 PM EDT, Apr 24 2014
(NY: MRK)  57.62  up arrow+0.12  (0.2 %)  Updated: 03:18 PM EDT, Apr 24 2014
(NQ: Microsoft Corp)  39.78  up arrow+0.09  (0.22 %)  Updated: 03:18 PM EDT, Apr 24 2014
(NQ: NetApp)  35.65  down arrow-0.22  (-0.61 %)  Updated: 03:17 PM EDT, Apr 24 2014
(NY: NOVARTIS AG)  84.75  down arrow-1.42  (-1.65 %)  Updated: 03:18 PM EDT, Apr 24 2014
(OP: Novozymes A/S)  47.51  up arrow+0.52  (1.11 %)  Updated: 03:17 PM EDT, Apr 24 2014
(NY: PFIZER)  30.73  down arrow-0.19  (-0.6 %)  Updated: 03:18 PM EDT, Apr 24 2014
(NQ: Pozen)  9.55  up arrow+0.33  (3.58 %)  Updated: 03:17 PM EDT, Apr 24 2014
(NY: RED HAT)  49.70  down arrow-0.35  (-0.7 %)  Updated: 03:17 PM EDT, Apr 24 2014
(NQ: BBRY)  7.33  down arrow-0.03  (-0.41 %)  Updated: 03:17 PM EDT, Apr 24 2014
(NQ: Salix)  110.48  up arrow+0.53  (0.48 %)  Updated: 03:17 PM EDT, Apr 24 2014
(NQ: SQI)  25.67  down arrow-0.51  (-1.95 %)  Updated: 03:17 PM EDT, Apr 24 2014

Posts tagged “OxyBio”

April 1

BD reboots startup program; NePhroGenex clinical trial; Red Hat Summit; OxyBio update; LabCorp board shuffle

Bulldog In the latest Bulldog roundup of life science and technology news: BD Technologies re-launches incubator program; NePhroGenex reports a loss for 2013 but secures providers for big clinical trial; Red Hat adds IBM exec to Summit lineup; OxyBio can resume testing; and LabCorp shuffles board.

December 11, 2013

Premium Lock Oxygen Bio picks DCRI for late-stage clinical trial on heart drug

Oxygen Biotherapeutics Oxygen Biotherapeutics is prepping to start late-stage clinical trials on a drug candidate that could treat low cardiac outpput syndrome and the company is tapping the cardiac surgery trials experience of the Duke Clinical Research Institute to do it.

November 14, 2013

Premium Lock Oxygen Bio closes on acquisition, names new CEO

OxyBio Oxygen Biotherapeutics now has a new chief executive officer with the closing of its Phyxius Pmara acquisition. On Thursday, the Morrisville-based company said John Kelley, the CEO of Phyxius, had formally taken over its CEO job.

November 8, 2013

Premium Lock Oxygen Bio nets $6M from warrants, boosts cash position ahead of clinical trials

OxyBio With the exercise of those warrants, Oxygen net $6 million giving the Morrisville-based company more cash to apply toward clinical trials for levosimendan, a drug being studied to treat acute decompensated heart failure. Read more about Oxygen's plans.

September 18, 2013

Premium Lock Oxygen Biotherapeutics slices $4.6M off its debt with stock deal

Oxygen Biotherapeutics The Morrisville-based life science firm says an unnamed investment fund has acquired 2.36 million shares of stock and has an option to buy the same number in the future. In exchange, the Triangle firm cuts its debt.

September 13, 2013

Premium Lock Oxygen Bio awarded patent for technology treating skin conditions

Oxygen Biotherapeutics Oxygen Biotherapeutics is seeking to out-license its technology for "non-core indications," including dermatology.

July 22, 2013

Premium Lock Oxygen Biotherapeutics raises $5.4M through stock offering

OxyBio The company says the fund will be used for clinical trials of its products.

May 16, 2013

Premium Lock OxyBio gets more time to show it meets NASDAQ listing rules

Oxygen Biotherapeutics The Nasdaq, which had sent Oxygen Biotherapeutics, a delisting notice in March, gives the company more time to show it meets listing requirements.

March 19, 2013

Premium Lock OxyBio weighs options to move TBI drug through trials

Oxygen Biotherapeutics Oxygen Biotherapeutics' (NASDAQ:OXBT) recent securities offering net $1.9 million -- enough to open clinical trial sites in Switzerland and Israel to study traumatic brain injury drug candidate Oxycyte. Beyond must take other financial steps.

November 21, 2012

Premium Lock Oxygen Biotherapeutics picks PPD to run clinical trial

PPD Oxygen Biotherapeutics picks PPD as the contract research organization to run a Phase 2 clinical trial on a proposed treatment for traumatic brain injury.

August 29, 2012

Premium Lock Oxygen Biotherapeutics is moving R&D lab to N.C.

OxyBio The drug firm has closed a facility in California and says it is seeking lab space in the Triangle.

July 26, 2012

Premium Lock Both revenue, loss rise at Oxygen Biotherapeutics

OxyBio Oxygen Biotherapeutics reported this week a net loss of $15.7 million for its recently completed fiscal year, up from a net loss of $10.4 million a year ago. Total net revenue did rise, though, to nearly $364,000 from last year.

March 2, 2012

Premium Lock RTP-based OxyBio terminates distribution agreements

OxyBio Oxygen Biotherapeutics says it will focus on sales of its skin product in North Carolina and South Florida.

February 2, 2012

Premium Lock Oxygen Biotherapeutics, partner to target strokes

OxyBio In an ischemic stroke, a clot blocks a vessel to the brain and deprives it of oxygen. Stroke treatments aim to salvage as much of the surrounding, salvageable brain tissue as possible.

December 13, 2011

Premium Lock Oxygen Biotherapeutics to raise $7.5M in private placement

OxyBio The funding follows a shakeup at Oxygen's executive offices and board. Former Chairman and CEO Chris Stern's positions at the company were terminated in August following an internal investigation that concluded Stern lied about his academic background and conducted undisclosed securities deals that he tried to cover up. Shortly afterward, two members of Oxygen's board of directors resigned after shareholders withheld their votes for the two directors.

October 11, 2011

Premium Lock Oxygen Biotherapeutics shakeup hits board of directors

Oxygen Biotherapeutics Two board members resign in the wake of disclosures of alleged improprieties leading to the ouster of former CEO Chris Stern.

Techwire Inside Partners
The Skinny: A Blog by Rick Smith

OUR INSIDERS

Dr. Mike Walden
Tech economy
Vivek Wadhwa
Commentary
Frank Vinluan
Life science
Scroll